ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimSustained-virological-response (SVR) after direct-acting-antiviral (DAA) therapy improves outcomes in patients with HCV-related compensated-advanced-chronic-liver-disease (cACLD). However, it remains unclear whether absolute post-SVR LSM or LSM reduction better predicts prognosis after SVR. This study evaluated the prognostic performance of absolute-values-LSM versus dynamic-change for predicting liver-related-events after SVR.
methodsWe retrospectively analysed patients with HCV-related cACLD treated with DAA between December 2014 and March 2022. Baseline and post-SVR non-invasive tests (LSM, FIB-4 and APRI) were assessed. Predictive performance for liver-related events was evaluated using time-dependent receiver operating characteristic analysis. Associations between Baveno-VII criteria for clinically significant LSM improvement and clinical outcomes were assessed using Fine-Grey competing-risk models.
resultsDuring a median of 60 months (95%; CI 52-69), 11/135 patients (8%) developed liver-related events. Patients who developed events had higher baseline LSM than those who remained event-free (24 vs. 18 kPa, p = 0.049), and higher follow-up LSM values (20 vs. 12 kPa, p = 0.043). Follow-up LSM showed good discriminative ability for liver-related events within the first 3 years after SVR (tAUC at 2 years: 0.86 [95% CI 0.75-0.97]; tAUC at 3 years: 0.82 [0.71-0.93]). Follow-up LSM was significantly superior to ΔLSM and percentage ΔLSM at both 2 and 3 years (all p ≤ 0.028). In competing-risk analysis, only follow-up LSM > 20 kPa was significantly associated with liver-related events (subdistribution hazard ratio 5.61, p = 0.007), whereas Baveno-VII criteria for LSM regression were not (SHR 0.33, p = 0.097).
conclusionsAbsolute post-treatment-LSM provides stronger prognostic information than dynamic changes from baseline. These findings support repeated post-SVR LSM assessment for risk stratification suggesting the relevance of residual liver disease in predicting liver-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.